The following should be read in conjunction with the consolidated financial statements, including the notes thereto, and Management's Discussion and Analysis of Financial Condition and Results of Operations beginning on page 25.
As of or for the Fiscal Year Ended September 30,
(Amounts in thousands, except per share amounts)
2018(a)
2017(b)
2016(c)
2015(d)
2014(e)
Statement of Operations Data:
Revenue
$
167,939,635
$
153,143,826
$
146,849,686
$
135,961,803
$
119,569,127
Gross profit
4,612,317
4,546,002
4,272,606
3,529,313
2,982,366
Operating expenses
3,168,632
3,485,660
2,746,832
3,107,093
2,200,275
Operating income
1,443,685
1,060,342
1,525,774
422,220
782,091
Interest expense, net
174,699
145,185
139,912
109,036
83,634
Income (loss) from continuing operations
1,615,892
364,484
1,427,929
(138,165
)
281,776
Net income (loss)
1,615,892
364,484
1,427,929
(138,165
)
274,230
Net income attributable to AmerisourceBergen Corporation
1,658,405
364,484
1,427,929
(138,165
)
274,230
Earnings per share from continuing operations — diluted
$
7.53
$
1.64
$
6.32
$
(0.63
)
$
1.20
Earnings per share — diluted
$
7.53
$
1.64
$
6.32
$
(0.63
)
$
1.16
Cash dividends declared per common share
$
1.52
$
1.46
$
1.36
$
1.16
$
0.94
Weighted average common shares outstanding — diluted
220,336
221,602
225,959
217,786
235,405
Balance Sheet Data:
Cash and cash equivalents
$
2,492,516
$
2,435,115
$
2,741,832
$
2,167,442
$
1,808,513
Accounts receivable, net
11,314,226
10,303,324
9,175,876
8,222,951
6,312,883
Merchandise inventories
11,918,508
11,461,428
10,723,920
9,755,094
8,593,852
Property and equipment, net
1,892,424
1,797,945
1,530,682
1,192,510
1,044,831
Total assets
37,669,838
35,316,470
33,637,501
27,962,982
21,677,432
Accounts payable
26,836,873
25,404,042
23,926,320
20,886,439
15,592,834
Total debt
4,310,189
3,442,055
4,186,703
3,493,048
1,995,632
Total equity
3,049,961
2,064,461
2,129,404
616,386
1,943,043
Total liabilities and stockholders' equity
$
37,669,838
$
35,316,470
$
33,637,501
$
27,962,982
$
21,677,432
(a)
Includes $61.3 million of employee severance, litigation, and other costs, net of income tax benefit of $122.2 million; a $59.7 million goodwill impairment with no income tax benefit; $48.6 million of LIFO expense, net of income tax benefit of $18.7 million; $47.8 million of PharMEDium remediation costs, net of income tax benefit of $18.4 million; a $42.3 million loss on consolidation of equity investments with no income tax benefit; a $30.0 million impairment on a non-customer note receivable with no income tax benefit; a $25.9 million gain from antitrust litigation settlements, net of income tax expense of $10.0 million; a $17.2 million loss on early retirement of debt, net of income tax benefit of $6.6 million; and $15.9 million of expense for an estimated assessment related to the New York State Opioid Stewardship Act, net of income tax benefit of $6.1 million.
(b)
Includes $101.1 million of LIFO credit, net of income tax expense of $56.7 million; a $0.9 million gain from antitrust litigation settlements, net of income tax expense of $0.5 million; and $937.4 million of employee severance, litigation, and other costs, net of income tax benefit of $21.9 million.
(c)
Includes $367.2 million of Warrants income, net of income tax benefit of $507.5 million; $120.9 million of LIFO expense, net of income tax benefit of $79.3 million; an $80.8 million gain from antitrust litigation settlements, net of income tax expense of $53.0 million; $62.1 million of employee severance, litigation, and other costs, net of income tax benefit of $40.8 million; and a $28.7 million pension settlement charge, net of income tax benefit of $18.9 million.
(d)
Includes $887.5 million of Warrants expense, net of income tax benefit of $25.3 million; $336.2 million of LIFO expense, net of income tax benefit of $206.6 million; a $40.6 million gain from antitrust litigation settlements, net of income tax expense of $24.9 million; a $30.6 million impairment charge on an equity investment, with no income tax benefit; and $23.5 million of employee severance, litigation, and other costs, net of income tax benefit of $14.4 million.
(e)
Includes $397.5 million of Warrants expense, net of income tax benefit of $25.2 million; $214.6 million of LIFO expense, net of income tax benefit of $133.4 million; $20.3 million of loss on early retirement of debt, net of income tax benefit of $12.7 million; a $15.1 million gain from antitrust litigation settlements, net of income tax expense of $9.3 million; and $5.1 million of employee severance, litigation, and other costs, net of income tax benefit of $3.1 million.
filings.tools